Hangying Ying1, Jiacheng Wang1, Zhida Shen1, Meihui Wang1, Binquan Zhou2. 1. Department of Cardiology, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, Zhejiang, China. 2. Department of Cardiology, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, Zhejiang, China. benzhou@hotmail.com.
Abstract
PURPOSE: To evaluate the potential association between the lowering of low-density lipoprotein cholesterol (LDL-C) with contemporary lipid-lowering medicines and cognitive function. METHODS: Randomized controlled trials (RCTs) in databases including PubMed, Embase, and the Web of Science and all databases in the Cochrane Library and ClinicalTrials.gov were collected from inception to January 1, 2020. The cognitive function of patients receiving proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, statins and ezetimibe was evaluated using meta-analysis. RESULTS: A total of 2910 studies were obtained from databases and other sources. Thirty-three studies were selected by screening, including 11 studies on alirocumab, 9 studies on evolocumab, 11 studies on statins and 2 studies on ezetimibe. In our study, a total of 128,691 patients with no cognitive impairment were divided into an intervention group (66,330 patients) and a control group (62,361 patients). The data were subjected to a random-effects model or a fixed-effects model for meta-analysis. The contemporary lipid-lowering medicines significantly reduced LDL-C in terms of both percentage (WMD: -45.06%, 95% CI -50.12% to -40.00%, P < 0.001) and absolute value (WMD: -64.01 mg/dL, 95% CI -72.25 to -55.78, P < 0.001). Compared with the control group, patients receiving treatment with contemporary lipid-lowering medicines did not show a significant difference in the rate of neurocognitive disorder (RR: 1.02, 95% CI 0.90 to 1.16, I2 = 0.0%, p = 0.696). Subgroup analysis was performed according to the intervention and LDL-C stratification. The result of this subgroup analysis was consistent with the main findings. Regarding global cognitive performance, no difference in major cognition was found among the pooled data (SMD: 0.02, 95% CI -0.01 to 0.04, P = 0.002), except for psychomotor speed (SMD: 0.09, 95% CI 0.02 to 0.16, P = 0.0024). CONCLUSIONS: Contemporary lipid-lowering medicines were not associated with cognitive impairment in RCTs. A low LDL-C level did not influence the incidence of cognitive disorder or global cognitive performance.
PURPOSE: To evaluate the potential association between the lowering of low-density lipoprotein cholesterol (LDL-C) with contemporary lipid-lowering medicines and cognitive function. METHODS: Randomized controlled trials (RCTs) in databases including PubMed, Embase, and the Web of Science and all databases in the Cochrane Library and ClinicalTrials.gov were collected from inception to January 1, 2020. The cognitive function of patients receiving proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, statins and ezetimibe was evaluated using meta-analysis. RESULTS: A total of 2910 studies were obtained from databases and other sources. Thirty-three studies were selected by screening, including 11 studies on alirocumab, 9 studies on evolocumab, 11 studies on statins and 2 studies on ezetimibe. In our study, a total of 128,691 patients with no cognitive impairment were divided into an intervention group (66,330 patients) and a control group (62,361 patients). The data were subjected to a random-effects model or a fixed-effects model for meta-analysis. The contemporary lipid-lowering medicines significantly reduced LDL-C in terms of both percentage (WMD: -45.06%, 95% CI -50.12% to -40.00%, P < 0.001) and absolute value (WMD: -64.01 mg/dL, 95% CI -72.25 to -55.78, P < 0.001). Compared with the control group, patients receiving treatment with contemporary lipid-lowering medicines did not show a significant difference in the rate of neurocognitive disorder (RR: 1.02, 95% CI 0.90 to 1.16, I2 = 0.0%, p = 0.696). Subgroup analysis was performed according to the intervention and LDL-C stratification. The result of this subgroup analysis was consistent with the main findings. Regarding global cognitive performance, no difference in major cognition was found among the pooled data (SMD: 0.02, 95% CI -0.01 to 0.04, P = 0.002), except for psychomotor speed (SMD: 0.09, 95% CI 0.02 to 0.16, P = 0.0024). CONCLUSIONS: Contemporary lipid-lowering medicines were not associated with cognitive impairment in RCTs. A low LDL-C level did not influence the incidence of cognitive disorder or global cognitive performance.
Authors: Christie M Ballantyne; Michael A Blazing; Thomas R King; William E Brady; Joanne Palmisano Journal: Am J Cardiol Date: 2004-06-15 Impact factor: 2.778
Authors: James Shepherd; Stuart M Cobbe; Ian Ford; Christopher G Isles; A Ross Lorimer; Peter W MacFarlane; James H McKillop; Christopher J Packard Journal: Atheroscler Suppl Date: 2004-10 Impact factor: 3.235
Authors: Karl Richardson; Marisa Schoen; Benjamin French; Craig A Umscheid; Matthew D Mitchell; Steven E Arnold; Paul A Heidenreich; Daniel J Rader; Emil M deGoma Journal: Ann Intern Med Date: 2013-11-19 Impact factor: 25.391
Authors: Donald M Lloyd-Jones; Pamela B Morris; Christie M Ballantyne; Kim K Birtcher; David D Daly; Sondra M DePalma; Margo B Minissian; Carl E Orringer; Sidney C Smith Journal: J Am Coll Cardiol Date: 2016-04-01 Impact factor: 24.094
Authors: Evan A Stein; Scott Mellis; George D Yancopoulos; Neil Stahl; Douglas Logan; William B Smith; Eleanor Lisbon; Maria Gutierrez; Cheryle Webb; Richard Wu; Yunling Du; Therese Kranz; Evelyn Gasparino; Gary D Swergold Journal: N Engl J Med Date: 2012-03-22 Impact factor: 91.245
Authors: Jonathan Cohen; Alexander Pertsemlidis; Ingrid K Kotowski; Randall Graham; Christine Kim Garcia; Helen H Hobbs Journal: Nat Genet Date: 2005-01-16 Impact factor: 38.330
Authors: Thomas Sudhop; Michael Reber; Diane Tribble; Aditi Sapre; William Taggart; Patrice Gibbons; Thomas Musliner; Klaus von Bergmann; Dieter Lütjohann Journal: J Lipid Res Date: 2009-04-20 Impact factor: 5.922
Authors: Katherine Samaras; Steve R Makkar; John D Crawford; Nicole A Kochan; Melissa J Slavin; Wei Wen; Julian N Trollor; Henry Brodaty; Perminder S Sachdev Journal: J Am Coll Cardiol Date: 2019-11-26 Impact factor: 24.094